Response to Comment on "Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma".
APA
Inoue H, Wang X, et al. (2026). Response to Comment on "Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma".. Journal of clinical pharmacology, 66(1), e70132. https://doi.org/10.1002/jcph.70132
MLA
Inoue H, et al.. "Response to Comment on "Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma".." Journal of clinical pharmacology, vol. 66, no. 1, 2026, pp. e70132.
PMID
41456953
같은 제1저자의 인용 많은 논문 (4)
- Intraoperative Indocyanine Green Imaging for Blood Flow Assessment in Very Small Remnant Stomach: A Case Report.
- Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation.
- Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.
- Effect of azelastine on PGE2 production in fibroblasts in normal skin. The possibility of inhibition of inducible cyclooxygenase by azelastine.